注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Aridis Pharmaceuticals Inc是一家處於後期階段的生物製藥公司。該公司專注於發現和開發利用全人單克隆抗體(mAbs)治療感染的靶向免疫療法。該公司的專有產品線由全人單克隆抗體組成,靶向與危及生命的細菌和病毒感染相關的特定病原體,主要是醫院獲得性肺炎(HAP)、呼吸機相關性肺炎(VAP)、囊性纖維化和COVID-19。該公司的主要候選產品AR-301針對革蘭氏陽性細菌金黃色葡萄球菌(S.aureus)產生的α毒素,這是一種與HAP和VAP相關的常見病原體。其臨床開發活動主要集中在AR-301、AR-712和AR-501。該公司開發的抗體發現和生產平台技術aPEXTM擴展了其現有的差異化抗體發現平台mabigail的能力。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Steven Michael Opal | - | - | Member Scientific Advisory Board |
John F. Hamilton | 78 | 2015 | Independent Director |
Jean Chastre | - | 2016 | Member of Clinical Advisory Board |
Bruno Francois | - | 2016 | Member of Clinical Advisory Board |
John S. Patton | 75 | - | Member of the Scientific Advisory Board |
Alan H. Cohen | 62 | 2017 | Member of Clinical Advisory Board |
Marin H. Kollef | 66 | 2016 | Member of Clinical Advisory Board |
Jerry Pier | - | - | Member of the Scientific Advisory Board |
David Salisbury | - | 2019 | Member of Scientific Advisory Board |
Harry B. Greenberg | - | - | Member of Scientific Advisory Board |
Susan R. Windham-Bannister | 72 | 2019 | Independent Director |
Vu L. Truong | 59 | 2003 | Founder, CEO, Chief Scientific Officer & Director |
Eric J. Patzer | 74 | 2003 | Founder & Executive Chairman |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核